Literature DB >> 23596295

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Lucas Sánchez-Sampedro1, Carmen Elena Gómez, Ernesto Mejías-Pérez, Eva Pérez-Jiménez, Juan Carlos Oliveros, Mariano Esteban.   

Abstract

Replication-competent poxvirus vectors with an attenuation phenotype and with a high immunogenic capacity of the foreign expressed antigen are being pursued as novel vaccine vectors against different pathogens. In this investigation, we have examined the replication and immunogenic characteristics of two vaccinia virus (VACV) mutants, M65 and M101. These mutants were generated after 65 and 101 serial passages of persistently infected Friend erythroleukemia (FEL) cells. In cultured cells of different origins, the mutants are replication competent and have growth kinetics similar to or slightly reduced in comparison with those of the parental Western Reserve (WR) virus strain. In normal and immune-suppressed infected mice, the mutants showed different levels of attenuation and pathogenicity in comparison with WR and modified vaccinia Ankara (MVA) strains. Wide genome analysis after deep sequencing revealed selected genomic deletions and mutations in a number of viral open reading frames (ORFs). Mice immunized in a DNA prime/mutant boost regimen with viral vectors expressing the LACK (Leishmania homologue for receptors of activated C kinase) antigen of Leishmania infantum showed protection or a delay in the onset of cutaneous leishmaniasis. Protection was similar to that triggered by MVA-LACK. In immunized mice, both polyfunctional CD4(+) and CD8(+) T cells with an effector memory phenotype were activated by the two mutants, but the DNA-LACK/M65-LACK protocol preferentially induced CD4(+) whereas DNA-LACK/M101-LACK preferentially induced CD8(+) T cell responses. Altogether, our findings showed the adaptive changes of the WR genome during long-term virus-host cell interaction and how the replication competency of M65 and M101 mutants confers distinct biological properties and immunogenicity in mice compared to those of the MVA strain. These mutants could have applicability for understanding VACV biology and as potential vaccine vectors against pathogens and tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596295      PMCID: PMC3676094          DOI: 10.1128/JVI.03013-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  The conserved poxvirus L3 virion protein is required for transcription of vaccinia virus early genes.

Authors:  Wolfgang Resch; Bernard Moss
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Poxvirus multiprotein entry-fusion complex.

Authors:  Tatiana G Senkevich; Suany Ojeda; Alan Townsley; Gretchen E Nelson; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

3.  MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.

Authors:  Eva Pérez-Jiménez; Grazyna Kochan; M Magdalena Gherardi; Mariano Esteban
Journal:  Microbes Infect       Date:  2006-01-13       Impact factor: 2.700

4.  Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035).

Authors:  Dawn Eckert; Ollie Williams; Clement A Meseda; Michael Merchlinsky
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Predicted function of the vaccinia virus G5R protein.

Authors:  Melissa Da Silva; Ling Shen; Vasily Tcherepanov; Cristalle Watson; Chris Upton
Journal:  Bioinformatics       Date:  2006-10-04       Impact factor: 6.937

6.  Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Authors:  Fernando Abaitua; Juan Ramón Rodríguez; Ana Garzón; Dolores Rodríguez; Mariano Esteban
Journal:  Virus Res       Date:  2005-10-07       Impact factor: 3.303

7.  Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its self-association.

Authors:  Silvia Palacios; Laurent H Perez; Sonja Welsch; Sibylle Schleich; Katarzyna Chmielarska; Frauke Melchior; Jacomine Krijnse Locker
Journal:  Mol Biol Cell       Date:  2005-03-30       Impact factor: 4.138

8.  Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.

Authors:  Jacqueline Weyer; Charles E Rupprecht; Janet Mans; Gerrit J Viljoen; Louis H Nel
Journal:  Vaccine       Date:  2007-03-22       Impact factor: 3.641

Review 9.  Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action.

Authors:  M A García; J Gil; I Ventoso; S Guerra; E Domingo; C Rivas; M Esteban
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

10.  Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response.

Authors:  Reinhard Obst; Hisse-Martien van Santen; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307

View more
  5 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

3.  Establishment and characterization of transformed goat primary cells by expression of simian virus 40 large T antigen for orf virus propagations.

Authors:  Yumiko Yamada; Guan-Ru Liao; Ching-Yu Tseng; Yeu-Yang Tseng; Wei-Li Hsu
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

4.  Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.

Authors:  Laura Fernández; Eugenia Carrillo; Lucas Sánchez-Sampedro; Carmen Sánchez; Ana Victoria Ibarra-Meneses; M Angeles Jimenez; Valter Dos Anjos Almeida; Mariano Esteban; Javier Moreno
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

5.  A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria.

Authors:  Gandharva Nagpal; Salman Sadullah Usmani; Gajendra P S Raghava
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.